AOD 9604.

AOD 9604 is a research compound in the igf axis & growth-factor peptides.

Its biological effect is described in the mechanism section.

It draws interest for igf axis & growth-factor peptides.

D-tier evidence: human evidence is limited; most support is preclinical.

What it is

AOD-9604 ("Advanced Obesity Drug 9604") is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic region of human growth hormone (hGH), residues 177–191, with an added tyrosine at the N-terminus. It was engineered in the 1990s by researchers at Monash University and developed by the Australian biotech Metabolic Pharmaceuticals as an orally-investigated anti-obesity agent. The design goal was to isolate hGH's fat-mobilizing activity while leaving out the growth-promoting, IGF-1-stimulating actions of the full hormone.

How it works

In rodent models, AOD-9604 reproduces the lipolytic (fat-breakdown) and fat-oxidation–promoting effects of full-length growth hormone without binding the GH receptor and without raising IGF-1. Mechanistic work in obese and beta-3-adrenergic-receptor knockout mice indicated its effect on fat metabolism is associated with modulation of beta-3 adrenergic receptor activity and increased lipolysis and fat oxidation rather than classic GH-receptor signaling. Because it does not engage the GH receptor, it was hypothesized to avoid the insulin-resistance and tissue-growth liabilities of GH itself. Importantly, the cleanly receptor-independent, IGF-1-sparing profile is best characterized in animal and in-vitro work, not firmly established in humans.

What the evidence shows

Preclinical evidence is the strongest part of the AOD-9604 record: chronic dosing reduced body-weight gain and increased fat oxidation in obese mice (Heffernan et al., Int J Obes, 2001; PMID 11673763). It progressed into human obesity trials in the early-mid 2000s; a 12-week randomized study reported only a modest separation from placebo (on the order of ~1–2 kg), and development was halted around 2007 after a larger ~24-week trial failed to show meaningful weight-loss efficacy, particularly once diet and exercise were standardized. No peer-reviewed pivotal trial demonstrates clinically useful weight loss, and there is no robust human evidence for the commonly marketed claims around cartilage, joint, or tendon repair — those rest on limited preclinical/early work. In short, the human data are negative-to-thin for obesity and largely absent for other indications.

Safety considerations

Across the obesity trials, AOD-9604 was generally reported as well tolerated with a clean short-term safety signal, which is part of why it was later nominated for compounding review; however, these data come from time-limited studies and do not establish long-term safety. There is no established safety profile for chronic use, for injectable research-grade ("gray market") product, or for the unindicated cosmetic, joint, and anti-aging uses now marketed online. Purity, identity, and contamination of non-pharmaceutical material are real concerns, underscored by published forensic identification of illicit AOD9604 preparations (Drug Testing and Analysis, 2014; PMID 24976118). No dosing or administration guidance is provided here.

Regulatory status

AOD-9604 is not approved by the FDA (or any major regulator) for any therapeutic use; its obesity development program was discontinued, and it remains investigational/research-use-only. The FDA has evaluated it among nominated bulk drug substances for pharmacy compounding under section 503A and has flagged peptide candidates of this type as raising significant safety questions; it is also prohibited in sport and tested for by anti-doping authorities under the WADA framework.

1. [1]Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment — International Journal of Obesity and Related Metabolic Disorders, 2001, PMID: 11673763
2. [2]Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604 — Drug Testing and Analysis, 2014, PMID: 24976118
3. [3]PubMed search: AOD9604 (all indexed literature) — PubMed/NCBI, ~22 records as of 2026
4. [4]Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks / 503A nominated substances — U.S. FDA, Human Drug Compounding

• Not FDA-approved for weight loss; research-only.
• Marketed claims outrun the underwhelming human trial results.

Stack fit

Why not C: held back by human evidence, safety clarity, regulatory clarity, practical relevance.

Why not F: supported by its overall evidence profile.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• AOD 9604 is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the IGF axis & growth-factor peptides class.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The preclinical evidence lane
3. Why Early, and not higher or lower
4. Proven lane vs speculative lane
5. What people report
6. Regulatory status
7. What changed recently